Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$154.35 - $166.11 $4,630 - $4,983
30 Added 0.62%
4,905 $811,000
Q1 2023

May 15, 2023

SELL
$151.05 - $180.26 $113,287 - $135,195
-750 Reduced 13.33%
4,875 $755,000
Q4 2022

Feb 14, 2023

SELL
$160.2 - $179.79 $124,154 - $139,337
-775 Reduced 12.11%
5,625 $993,000
Q3 2022

Nov 14, 2022

SELL
$161.33 - $179.52 $8,066 - $8,976
-50 Reduced 0.78%
6,400 $1.05 Million
Q1 2022

May 16, 2022

BUY
$158.14 - $179.59 $114,651 - $130,202
725 Added 12.66%
6,450 $1.14 Million
Q4 2021

Feb 14, 2022

SELL
$155.93 - $173.01 $62,372 - $69,204
-400 Reduced 6.53%
5,725 $979,000
Q3 2021

Nov 12, 2021

SELL
$161.5 - $179.47 $161 - $179
-1 Reduced 0.02%
6,125 $989,000
Q2 2021

Aug 13, 2021

SELL
$159.48 - $171.07 $27,749 - $29,766
-174 Reduced 2.76%
6,126 $1.01 Million
Q3 2018

Nov 14, 2018

BUY
$121.58 - $142.88 $30,395 - $35,720
250 Added 4.13%
6,300 $870,000
Q2 2018

Aug 14, 2018

BUY
$119.4 - $131.76 $59,700 - $65,880
500 Added 9.01%
6,050 $734,000
Q4 2017

Feb 14, 2018

SELL
$131.22 - $143.62 $26,244 - $28,724
-200 Reduced 3.48%
5,550 $775,000
Q3 2017

Nov 14, 2017

BUY
$129.47 - $135.38 $744,452 - $778,435
5,750
5,750 $747,000

Others Institutions Holding JNJ

About JOHNSON & JOHNSON


  • Ticker JNJ
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,614,479,872
  • Market Cap $401B
  • Description
  • Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the...
More about JNJ
Track David Rolfe's Portfolio

Track David Rolfe Portfolio

Follow David Rolfe (Wedgewood Partners Inc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wedgewood Partners Inc, based on Form 13F filings with the SEC.

News

Stay updated on Wedgewood Partners Inc and David Rolfe with notifications on news.